Anti-Human CTLA4 Recombinant Antibody (Ipilimumab) (CAT#: TAB-067)

Recombinant monoclonal antibody to CTLA4. Ipilimumab (known as MDX-010 and MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody, and works by activating the immune system by targeting CTLA-4.
Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy cancer cells.

Host: Human

Isotype: IgG1 - kappa

Applications: WB, FuncS, IF, Neut, ELISA, FC, IP, IHC


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
IHC

Figure 1 Intratumoral blood vessel changes from treatment with bevacizumab plus ipilimumab in subcutaneous melanoma deposits.

A, characterization of tumor-associated vasculature before and while on therapy. Endothelial cells lining small vessels within melanomas of ipilimumab plus bevacizumab–treated patients were rounded and columnar as assessed by hematoxylin and eosin (H&E) and CD31 staining, in contrast with pretreatment samples and on-treatment samples from patients receiving ipilimumab alone (column to extreme right; v, vessel). Scale bar, 50 microns. Endothelial cells in tumor deposits of patients receiving ipilimumab plus bevacizumab were also associated with increased expression of E-selectin, and adhesion and diapedesis of CD8+ T cells. Enlarged central panels highlight the focally occlusive appearance of this endothelial activation [top, H&E; bottom, CD31; inset, E-selectin)]. Base membrane of vessels approximated by dotted lines.

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T.,... & Friedlander, P. (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer immunology research, 2(7), 632-642.

IHC

Figure 2 Histologic changes in tumor deposits resulting from treatment with bevacizumab plus ipilimumab.

A, phenotypic characterization of immune-cell infiltrates in biopsies from responders before and after initiation of therapy. Tumors after initiation (ON) of ipilimumab–bevacizumab therapy were characterized as compared with pretreatment samples (PRE). Significant infiltration by CD3+CD8+ T cells and CD163+ macrophages with minimal change in Foxp3+ component was observed. The enlarged panels (center) emphasize the tumor-infiltrating architecture of the immune response (top left, skeletal muscle). In contrast, patients treated only with ipilimumab showed a lesser degree of immune-cell infiltration while on therapy. The two ipilimumab–bevacizumab specimens are subcutaneous tissues, and the ipilimumab-alone specimen was from the oropharyngeal submucosa.

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T.,... & Friedlander, P. (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer immunology research, 2(7), 632-642.

FC

Figure 3 Cellular and humoral immune responses in the peripheral blood are altered by the addition of bevacizumab to ipilimumab.

All samples were obtained pretreatment and at week 12 at the completion of ipilimumab or ipilimumab–bevacizumab induction. A, example of changes as a function of treatment in CD4+CCR7+CD45RO+ and CD4+CCR7−CD45RO+ T-cell populations to ipilimumab plus bevacizumab treatment, compared with changes with ipilimumab treatment alone. B, example of changes as a function of treatment in CD8+CCR7+CD45RO+ and CD8+CCR7−CD45RO+ T-cell populations to ipilimumab plus bevacizumab treatment, compared with the responses to ipilimumab treatment alone. C, number of patients with melanoma who have at least 50% enhancement in CD4+/CD8+ CCR7+CD45RO+ and CD4+/CD8+ CCR7−CD45RO+ T-cell populations following treatment with ipilimumab (3 mg/kg), or ipilimumab (3 mg/kg) plus bevacizumab, or ipilimumab (10 mg/kg) plus bevacizumab. *, P < 0.05 between ipilimumab and ipilimumab plus bevacizumab; **, P < 0.01. D, representative immunoblots of antibody responses in 4 bevacizumab plus ipilimumab–treated patients to a total of zero, one, two, or three galectins. Arrows, increased antibody levels in posttreatment sera samples. Galectin-1, -3, and -9 proteins were mixed together and equally loaded and separated by gel electrophoresis. Following transfer onto a membrane, strips were incubated with equally diluted pretreatment and posttreatment sera. Density analysis using NIH ImageJ software confirmed the increases in densities of the indicated bands after subtracting background taken from nearby areas of each band. As in most of the cases, density change was seen in only one or two of the three galectins; protein(s) without density change served as loading controls. E, antibody responses to galectins in patients treated with bevacizumab plus ipilimumab and ipilimumab alone. Anti-galectin-1, anti-galectin-3, and anti-galectin-9 antibodies were detected in pretreatment and posttreatment patient sera by immunoblot analyses. Percentages of patients with increased levels of antibodies to a total of zero, one, two, or three galectins in bevacizumab plus ipilimumab-treated patients (n = 45) and ipilimumab-alone patients (n = 18). Density of each band was measured using NIH ImageJ software and the antibody fold change was calculated using the formula: fold change = (densityPost − densityPre)/densityPre. Antibody levels were considered as increased when the fold change ≥ 0.5.

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T.,... & Friedlander, P. (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer immunology research, 2(7), 632-642.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • WB, FuncS, IF, Neut, ELISA, FC, IP, IHC
  • Trade name
  • yervoy
  • CAS
  • 477202-00-9
  • Generic Name
  • Ipilimumab
  • ATC Code
  • L01XC11
  • UNII
  • 6T8C155666
  • MW
  • 148,634.914 g/mol
  • Related Disease
  • Melanoma, metastatic

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • 4°C. For long term storage, aliquot and store at -20°C. Repeated thawing and freezing must be avoided.

Applications

  • Application Notes
  • The CTLA4 antibody has been reported in applications of WB, FuncS, IF, Neut, ELISA, FC, IP, IHC.

Target

  • Alternative Names
  • Ipilimumab;yervoy;477202-00-9;MDX-010;MDX-101;Yervoy;MDX-010;MDX-101;CTLA4;cytotoxic T-lymphocyte-associated protein 4;celiac disease 3 , CELIAC3;cytotoxic T-lymphocyte protein 4;CD;CD28;CD152;GSE;ICOS;CD152 isoform;celiac disease 3;cytotoxic T-lymphocyte

Related Resources

  • Related Diseases

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Ipilimumab"

Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ipilimumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTLA4. Ipilimumab (known as MDX-010 and MDX-101), marketed as Yervoy, is a drug used for the treatment of melanoma, a type of skin cancer. It is a U.S. Food and Drug Administration (FDA) approved human monoclonal antibody, and works by activating the immune system by targeting CTLA-4.
Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy cancer cells.

See other products for "CTLA4"

Human Antibody

CAT Product Name Application Type
TAB-206 Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) WB, IF, IP, Neut, FuncS, ELISA, FC IgG2

Immunotoxin

CAT Product Name Application Type
AGTO-G015E Anti-CTLA4 immunotoxin (scFv)-PE Cytotoxicity assay, Function study
AGTO-G015S Anti-CTLA4 immunotoxin (scFv)-Sap Cytotoxicity assay, Function study
AGTO-G015M Anti-CTLA4 immunotoxin (scFv)-Mel Cytotoxicity assay, Function study

Rat Antibody

CAT Product Name Application Type
TAB-195CL Mouse Anti-CTLA4 Recombinant Antibody (TAB-195CL) ELISA Mouse IgG

Chimeric Antibody

CAT Product Name Application Type
TAB-085MZ Anti-Human CTLA4 Recombinant Antibody (TGN2122.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-085MZ-S(P) Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2122.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-086MZ-S(P) Anti-Human CTLA4 Recombinant Antibody scFv Fragment (TGN2422.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-085MZ-F(E) Anti-Human CTLA4 Recombinant Antibody Fab Fragment (TGN2122.C) ELISA, FC Chimeric antibody (mouse/human)
TAB-086MZ-F(E) Anti-Human CTLA4 Recombinant Antibody Fab Fragment (TGN2422.C) ELISA, FC Chimeric antibody (mouse/human)

Humanized Antibody

CAT Product Name Application Type
TAB-083MZ-F(E) Anti-Human CTLA4 Recombinant Antibody Fab Fragment (TGN2122.H) ELISA, FC Humanized antibody
TAB-084MZ-F(E) Anti-Human CTLA4 Recombinant Antibody Fab Fragment (TGN2422.H) ELISA, FC Humanized antibody
TAB-088MZ-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (TAB-088MZ-F(E)) ELISA Humanized Fab
TAB-091MZ-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (TAB-091MZ-F(E)) ELISA Humanized Fab
TAB-092MZ-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (TAB-092MZ-F(E)) ELISA Humanized Fab

Mouse Antibody

CAT Product Name Application Type
TAB-087MZ-F(E) Mouse Anti-CTLA4 Recombinant Antibody; Fab Fragment (TAB-087MZ-F(E)) ELISA Mouse Fab
TAB-089MZ-F(E) Mouse Anti-CTLA4 Recombinant Antibody; Fab Fragment (TAB-089MZ-F(E)) ELISA Mouse Fab
TAB-090MZ-F(E) Mouse Anti-CTLA4 Recombinant Antibody; Fab Fragment (TAB-090MZ-F(E)) ELISA Mouse Fab
TAB-093MZ-F(E) Anti-Human CTLA4 Recombinant Antibody Fab Fragment (Mu-26B) ELISA
MOB-0317MC Recombinant Mouse Anti-CTLA4 Antibody ELISA, FACS

Neutralizing Antibody

CAT Product Name Application Type
NEUT-567CQ Mouse Anti-CTLA4 Recombinant Antibody (clone 14D3) FC, FuncS, Neut, IP, WB Mouse IgG2a, κ
NEUT-569CQ Mouse Anti-CTLA4 Recombinant Antibody (clone AS32) WB, Neut Mouse IgG1
NEUT-570CQ Human Anti-CTLA4 Recombinant Antibody (clone YC030) Neut Human IgG1, κ
NEUT-572CQ Hamster Anti-Ctla4 Recombinant Antibody (clone UC10-4B9) FC, Block, ELISA, IP Hamster IgG
NEUT-580CQ Rat Anti-Ctla4 Recombinant Antibody (clone CBL855) FC, Neut, WB Rat IgG2

Blocking Antibody

CAT Product Name Application Type
NEUT-568CQ Mouse Anti-CTLA4 Recombinant Antibody (clone L3D10) FC, Block Mouse IgG1, κ
NEUT-571CQ Mouse Anti-CTLA4 Recombinant Antibody (clone BN13) Block, FC Mouse IgG2a
NEUT-577CQ Hamster Anti-Ctla4 Recombinant Antibody (clone MAB0835) Block, FC Hamster IgG
NEUT-578CQ Hamster Anti-Ctla4 Recombinant Antibody (clone RYNmCTLA-4) Block Hamster IgG
NEUT-581CQ Hamster Anti-Ctla4 Recombinant Antibody (clone UC10-4F10-11) Block, FC, WB Hamster IgG

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0855 Hi-Affi™ Rabbit Anti-CTLA4 Recombinant Antibody (clone DS855AB) WB Rabbit IgG

Recombinant Antibody

CAT Product Name Application Type
HPAB-0051-YC Human Anti-CTLA4 Recombinant Antibody (clone 10D1) ELISA, Cyt, Block Human IgG, κ
HPAB-610-FY Human Anti-CTLA4 Recombinant Antibody (HPAB-610-FY) ELISA Human IgG
HPAB-611-FY Human Anti-CTLA4 Recombinant Antibody (HPAB-611-FY) ELISA Human IgG
HPAB-M0494-YC Human Anti-CTLA4 Recombinant Antibody (HPAB-M0494-YC) ELISA, FC, Block, FuncS Human IgG1
HPAB-M0495-YC Human Anti-CTLA4 Recombinant Antibody (HPAB-M0495-YC) ELISA, Block Human IgG

Fab Fragment Antibody

CAT Product Name Application Type
HPAB-0051-YC-F(E) Human Anti-CTLA4 Recombinant Antibody (clone 10D1); Fab Fragment ELISA, Cyt, Block Human Fab
HPAB-0157-FY-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0157-FY-F(E)) Activ Humanized Fab
HPAB-N0343-YC-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-N0343-YC-F(E)) FC, ELISA Human Fab
HPAB-0749LY-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0749LY-F(E)) FuncS, ELISA Human Fab
HPAB-0750LY-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-0750LY-F(E)) FuncS, ELISA Human Fab

scFv Fragment Antibody

CAT Product Name Application Type
HPAB-0306-FY-S(P) Human Anti-CTLA4 Recombinant Antibody (clone IBI310); scFv Fragment WB Human scFv
HPAB-1097-FY-F(E) Hamster Anti-Ctla4 Recombinant Antibody (clone FY-002); scFv Fragment ELISA Hamster scFv
HPAB-1098-FY-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-1098-FY-F(E)) ELISA Human Fab
HPAB-1099-FY-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-1099-FY-F(E)) ELISA Human Fab
HPAB-1100-FY-F(E) Human Anti-CTLA4 Recombinant Antibody; Fab Fragment (HPAB-1100-FY-F(E)) ELISA Human Fab

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-067 Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ipilimumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC ADCC enhanced antibody
AFC-TAB-206 Afuco™ Anti-CTLA4 ADCC Recombinant Antibody (Ticilimumab (= Tremelimumab)), ADCC Enhanced IF, IP, Neut, FuncS, ELISA ADCC enhanced antibody

Single-domain Antibody

CAT Product Name Application Type
HPAB-AP860-YC Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP860-YC) ELISA, Block Camel VHH
HPAB-AP861-YC Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP861-YC) ELISA, Block Camel VHH
HPAB-AP862-YC Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP862-YC) ELISA, Block Camel VHH
HPAB-AP863-YC Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP863-YC) ELISA, Block Camel VHH
HPAB-AP864-YC Camelid Anti-CTLA4 Recombinant Antibody; VHH Fragment (HPAB-AP864-YC) ELISA, Block Camel VHH

Customer Reviews and Q&As

Submit a review or a question
Thare are currently no Customer reviews or questions for TAB-067. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
WBWestern Blot

Send Inquiry

© 2023 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart